{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T16:33:58Z","timestamp":1793205238743,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jacc.2023.04.052","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T14:00:03Z","timestamp":1688392803000},"page":"161-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"title":["Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease"],"prefix":"10.1016","volume":"82","author":[{"given":"Javier","family":"Morales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Handelsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2023.04.052_bib1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2337\/db20211-13","article-title":"The interplay between diabetes, cardiovascular disease, and kidney disease","author":"Usman","year":"2021","journal-title":"ADA Clinical Compendia"},{"key":"10.1016\/j.jacc.2023.04.052_bib2","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.04.052_bib3","first-page":"2505","article-title":"How to assess diabetic kidney disease progression? From albuminuria to GFR","volume":"10","author":"Garc\u00eda-Carro","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jacc.2023.04.052_bib4","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"395","author":"Bikbov","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2023.04.052_bib5","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.pop.2020.08.004","article-title":"Diabetic kidney disease","volume":"47","author":"Bonner","year":"2020","journal-title":"Prim Care: Clin Off Pract"},{"key":"10.1016\/j.jacc.2023.04.052_bib6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2023.04.052_bib7","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2023.04.052_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12020-017-1517-9","article-title":"Glycemic control in type 2 diabetes: from medication nonadherence to residual vascular risk","volume":"61","author":"Giugliano","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.jacc.2023.04.052_bib9","first-page":"385","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"174","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2023.04.052_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.13969","article-title":"Pathophysiologic mechanisms in diabetic kidney disease: a focus on current and future therapeutic targets","volume":"22","author":"Barrera-Chimal","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jacc.2023.04.052_bib11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12933-018-0762-4","article-title":"Association between insulin resistance and the development of cardiovascular disease","volume":"17","author":"Ormazabal","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2023.04.052_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2021.108101","article-title":"DCRM multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases","volume":"36","author":"Handelsman","year":"2022","journal-title":"J\u00a0Diabetes Complicat"},{"key":"10.1016\/j.jacc.2023.04.052_bib13","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrcardio.2016.163","article-title":"Neurohormonal activation in heart failure with reduced ejection fraction","volume":"14","author":"Hartupee","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2023.04.052_bib14","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2023.04.052_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cells11182917","article-title":"Diabetic proteinuria revisited: updated physiologic perspectives","volume":"11","author":"Heyman","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jacc.2023.04.052_bib16","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2023.04.052_bib17","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40265-020-01290-3","article-title":"ACE inhibitor benefit to kidney and cardiovascular outcomes for patients with non-dialysis chronic kidney disease stages 3-5: a network meta-analysis of randomised clinical trials","volume":"80","author":"Zhang","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.jacc.2023.04.052_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2023.04.052_bib19","first-page":"632","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"J\u00a0Am Coll Cardiol Basic Trans Science"},{"key":"10.1016\/j.jacc.2023.04.052_bib20","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.04.052_bib21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2023.04.052_bib22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.04.052_bib23","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2023.04.052_bib24","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12933-022-01476-x","article-title":"Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis","volume":"21","author":"Kaze","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2023.04.052_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100933","article-title":"SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis","volume":"36","author":"Cardoso","year":"2021","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jacc.2023.04.052_bib26","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.04.052_bib27","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.04.052_bib28","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.04.052_bib29","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1080\/00325481.2021.2009726","article-title":"Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations","volume":"134","author":"Shubrook","year":"2022","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jacc.2023.04.052_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/14791641211011016","article-title":"Safety of four SGLT2 inhibitors in three chronic diseases: a meta-analysis of large randomized trials of SGLT2 inhibitors","volume":"18","author":"Qiu","year":"2021","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.jacc.2023.04.052_bib31","first-page":"947","article-title":"GLP-1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists","volume":"9","author":"G\u00f3rriz","year":"2020","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jacc.2023.04.052_bib32","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.04.052_bib33","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.04.052_bib34","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2023.04.052_bib35","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2023.04.052_bib36","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1007\/s13300-020-00917-8","article-title":"Semaglutide: charting new horizons in GLP-1 analogue outcome studies","volume":"11","author":"Williams","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jacc.2023.04.052_bib37","doi-asserted-by":"crossref","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"Trujillo","year":"2021","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.jacc.2023.04.052_bib38","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2023.04.052_bib39","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2023.04.052_bib40","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.04.052_bib41","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.04.052_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2023.04.052_bib43","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10741-019-09832-y","article-title":"Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials","volume":"25","author":"Frankenstein","year":"2020","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jacc.2023.04.052_bib44","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/phar.2633","article-title":"Cardiovascular and kidney outcomes of spironolactone or eplerenone in combination with ACEI\/ARBs in patients with diabetic kidney disease","volume":"41","author":"An","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacc.2023.04.052_bib45","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A\u00a0randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.04.052_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2022.102638","article-title":"Finerenone in diabetic kidney disease: a systematic review and critical appraisal","volume":"16","author":"Singh","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.jacc.2023.04.052_bib47","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.04.052_bib48","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD Trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2023.04.052_bib49","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2023.04.052_bib50","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN)","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2023.04.052_bib51","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1253\/circrep.CR-21-0115","article-title":"Implication of mineralocorticoid receptor antagonist esaxerenone in patients with heart failure with preserved ejection fraction","volume":"3","author":"Imamura","year":"2021","journal-title":"Circ Rep"},{"key":"10.1016\/j.jacc.2023.04.052_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259485","article-title":"Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: a retrospective study","volume":"16","author":"Iwahana","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jacc.2023.04.052_bib53","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2023.04.052_bib54","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010254","article-title":"The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: a systematic review and meta-analysis","volume":"97","author":"Pei","year":"2018","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jacc.2023.04.052_bib55","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2023.04.052_bib56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/HYPERTENSIONAHA.121.18434","article-title":"Is the KDIGO systolic blood pressure target\u00a0<120\u00a0mm\u00a0Hg for chronic kidney disease appropriate in routine clinical practice?","volume":"79","author":"Dasgupta","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2023.04.052_bib57","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2337\/cd22-as01","article-title":"Standards of medical care in diabetes\u20142022 abridged for primary care providers","volume":"40","year":"2022","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.jacc.2023.04.052_bib58","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2337\/dci19-0066","article-title":"2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"43","author":"Buse","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2023.04.052_bib59","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4158\/CS-2019-0472","article-title":"Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm\u20142020 Executive Summary","volume":"26","author":"Garber","year":"2020","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jacc.2023.04.052_bib60","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1111\/dom.14801","volume":"24","author":"Yang","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.jacc.2023.04.052_bib61","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/ndt\/gfac198","article-title":"Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE)","volume":"38","author":"Green","year":"2023","journal-title":"Nephrol Dial Transplant"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723055948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109723055948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:57:13Z","timestamp":1760018233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109723055948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0735109723055948"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2023.04.052","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2023.04.052","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}